Jeena Sikho Lifecare Reports Strong Q2 FY26 Results; Concall Transcript Released with Growth Outlook
JSLL's Q2 FY26 concall transcript showed strong revenue and profit growth. Key updates: increased bed capacity, Chandan Diagnostic partnership, and 10 new OTC product launches by FY26 end.
The exceptional financial performance, particularly the substantial growth in profitability metrics, demonstrates strong business execution. The strategic partnership with Chandan Diagnostic and the planned launch of numerous OTC products are significant initiatives that could lead to substantial market expansion and revenue diversification, driving high impact on the company's future prospects.
The company reported significant year-on-year growth in revenue (66%), PAT (121%), and EBITDA (129%), indicating strong financial health. Surpassing annual bed targets in six months, coupled with strategic partnerships and aggressive new product launch plans, points to robust operational expansion and positive future outlook.
* Jeena Sikho Lifecare Limited (JSLL) released the transcript of its conference call held on 07th November 2025, discussing the financial results for the quarter ended 30th September 2025 (Q2 FY26). * Financial Highlights (Q2 FY26): * Revenue from operations stood at ₹190 crore, marking a 66% year-on-year (Y-o-Y) growth and 9% quarter-on-quarter (Q-o-Q) growth. * Profit After Tax (PAT) reached ₹59 crore, an increase of 121% Y-o-Y and 15% Q-o-Q. * EBITDA increased to ₹92 crore, reflecting a 129% Y-o-Y growth and 17% Q-o-Q growth, with an EBITDA margin of 48%. * Operational Updates: * The company's total bed capacity increased to 2,802, surpassing the year-end target of 2,850 beds within six months. Operational beds are 2,220, with an occupancy rate of 57%. * Inpatient Department (IPD) volume grew to 9,614 patients in Q2 from 8,616 in Q1, while Outpatient Department (OPD) volume rose to 1,40,144 from 1,24,364. * Average revenue per bed is ₹8,324. The company currently operates 58 hospitals, 59 clinics, and 35 franchises, including 46 NAVH centers with 5 more in the pipeline. * Strategic Initiatives: * A strategic partnership with Chandan Diagnostic will offer free basic blood tests for cardholders, with 34 centers now operational within JSLL locations. This tie-up leverages Chandan's NABL lab for health insurance claims and provides a 30% cashback to patients from Chandan's commission. * The OTC business saw the launch of the 'Pet Shuddhi kit,' generating ₹2.25 crore in online sales last month. JSLL plans to launch 15-20 new products, including medicines for BP, sugar, kidney, liver, and depression after clinical trials, with 10 products expected by the end of FY26. The company targets a ₹300-₹500 crore turnover from OTC/online products in the next 1-2 years. * One medical college in Mohali (Saraswati Group) with 100 beds is operational at 90% occupancy. Two other college takeovers in Vrindavan and Buldhana are ready but awaiting operationalization due to government formalities and a revised strategy. * A new card-driven referral system, integrated with Salesforce software, is being implemented to provide points and discounts to patients for referrals, medicine purchases, and Chandan Healthcare tests. * Future Outlook: * Management aims to increase bed occupancy to 80% and aspires for JSLL to become India's, then Asia's, and ultimately the world's leading naturopathy and Ayurveda healthcare provider. A VIP premium center is planned for launch within 2-4 months. * For FY26, the company maintains its guidance of ₹650-₹700 crore turnover and ₹125-₹130 crore profit, acknowledging potential seasonal weakness in Q3. The target PAT margin for the company and OTC business remains at 20-25%.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.